. "Taurocholate"@en . . "Reduces nicotine entry into the brain and thus the positive reinforcement associated with smoking."@en . "Cholyltaurine"@en . "investigational"@en . "Cholaic acid"@en . "TA-NIC"@en . "TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. TA-NIC is an immunotherapeutic vaccine similar in concept to TA-CD, designed to raise anti-nicotine antibodies. The antibodies bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain and thus reducing the positive reinforcement and addiction associated with nicotine and cigarette smoking. It is expected that the reduction of the positive reinforcement will in turn reduce the desire to smoke or use other tobacco products."@en . . . . "Investigated for use/treatment in tobacco dependence."@en . "# Goniewicz ML, Koszowski B, Czogala J, Zymelka A: [New prospects of nicotine dependence treatment--vaccines] Przegl Lek. 2006;63(10):1114-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17288232 # Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15648190 # Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines. 2004 Aug;3(4):386. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15270640 # Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8132774"@en . "TA-NIC consists of nicotine conjugated to the carrier protein rCTB and an aluminium adjuvant."@en . . "Appears to be well-tolerated."@en .